Optimizing biotherapeutic cell lines for continuous manufacturing

Cost pressure, market uncertainty, and market growth can create new challenges for manufacturing technologies. With the rise of more complex molecules often comes the challenge of manufacturing them cost-effectively. One approach that contract manufacturing organizations and drug development companies take to increase their manufacturing output is using perfusion and process-intensive technologies. However, a challenge in such efforts is the adaptation of cells to very different culture conditions, which requires a sufficiently flexible cell line and a good understanding of process requirements to maximize performance.

In this webinar, we hear from Dr. Jeff McGrew, Scientific Director at Just–Evotec Biologics, who has used the CHOSOURCE™ GS KO cell line to develop high producing cell lines rapidly. Several case studies show these cell lines’ capacity to achieve cell densities in the range of 100 million cells per mL in perfusion processes with high specific productivities. These cell lines’ ability to achieve both high cell density and high specific productivity helped Just–Evotec Biologics to implement an intensified low-cost manufacturing processes as part of their manufacturing process.

The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications under specific licenses from Revvity. The platform is also available for services under a service license from Revvity.